Columbamine (chloride)

Columbamine (Columbamin; Dehydroisocorypalmine) chloride is an organic heterotetracyclic alkaloid extracted from plants. Columbamine chloride is a metabolite of Berberine (HY-N0716) . Columbamine chloride inhibits the cytochrome P450 (CYP) isoform CYP3A4 (IC50 = 30.6 µM) . Columbamine chloride induces apoptosis in cancer cells. Columbamine chloride can be used for antioxidant, anti-inflammatory, antitumor, antifungal, antiparasite, hepatoprotective, neuroprotective, hypolipidemic and hypoglycemic study[1][2][3][4][5][6].

Product Specifications

CAS Number

[1916-10-5]

Product Name Alternative

Columbamin (chloride) ; Dehydroisocorypalmine (chloride)

UNSPSC

12352005

Target

Apoptosis; Cytochrome P450; Parasite

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease

Field of Research

Cancer; Infection; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/columbamine-chloride.html

Purity

99.62

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

COC1=C(OC)C2=C[N+]3=C(C4=CC(O)=C(OC)C=C4CC3)C=C2C=C1.[Cl-]

Molecular Formula

C20H20ClNO4

Molecular Weight

373.83

References & Citations

[1]Wang W, et al. A series of strategies for solving the shortage of reference standards for multi-components determination of traditional Chinese medicine, Mahoniae Caulis as a case. J Chromatogr A. 2015 Sep 18;1412:100-11.|[2]Wright CW, et al. In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids. J Nat Prod. 2000 Dec;63 (12) :1638-40.|[3]Cao S, et al. Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-activated protein kinase in Hep G2 cells. J Ethnopharmacol. 2013 Sep 16;149 (2) :576-82.|[4]Su CR, et al. Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria. J Nat Prod. 2007 Dec;70 (12) :1930-3.|[5]ei C, et al. Columbamine suppresses the proliferation and malignization of colon cancer cells via abolishing Wnt/β-catenin signaling pathway. Cancer Manag Res. 2019 Sep 23;11:8635-8645.